157 related articles for article (PubMed ID: 19596885)
1. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Sluis-Cremer N; Koontz D; Bassit L; Hernandez-Santiago BI; Detorio M; Rapp KL; Amblard F; Bondada L; Grier J; Coats SJ; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2009 Sep; 53(9):3715-9. PubMed ID: 19596885
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.
Meteer JD; Schinazi RF; Mellors JW; Sluis-Cremer N
Antiviral Res; 2014 Jan; 101():62-7. PubMed ID: 24211331
[TBL] [Abstract][Full Text] [Related]
3. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
Meteer JD; Koontz D; Asif G; Zhang HW; Detorio M; Solomon S; Coats SJ; Sluis-Cremer N; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2011 Aug; 55(8):3758-64. PubMed ID: 21646480
[TBL] [Abstract][Full Text] [Related]
4. Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs.
Herman BD; Schinazi RF; Zhang HW; Nettles JH; Stanton R; Detorio M; Obikhod A; Pradère U; Coats SJ; Mellors JW; Sluis-Cremer N
Nucleic Acids Res; 2012 Jan; 40(1):381-90. PubMed ID: 21914723
[TBL] [Abstract][Full Text] [Related]
5. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.
Cihlar T; Ray AS; Boojamra CG; Zhang L; Hui H; Laflamme G; Vela JE; Grant D; Chen J; Myrick F; White KL; Gao Y; Lin KY; Douglas JL; Parkin NT; Carey A; Pakdaman R; Mackman RL
Antimicrob Agents Chemother; 2008 Feb; 52(2):655-65. PubMed ID: 18056282
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
Zhang HW; Detorio M; Herman BD; Solomon S; Bassit L; Nettles JH; Obikhod A; Tao SJ; Mellors JW; Sluis-Cremer N; Coats SJ; Schinazi RF
Eur J Med Chem; 2011 Sep; 46(9):3832-44. PubMed ID: 21700368
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Agarwal HK; Buckheit KW; Buckheit RW; Parang K
Bioorg Med Chem Lett; 2012 Sep; 22(17):5451-4. PubMed ID: 22858097
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.
Zhang HW; Coats SJ; Bondada L; Amblard F; Detorio M; Asif G; Fromentin E; Solomon S; Obikhod A; Whitaker T; Sluis-Cremer N; Mellors JW; Schinazi RF
Bioorg Med Chem Lett; 2010 Jan; 20(1):60-4. PubMed ID: 19948402
[TBL] [Abstract][Full Text] [Related]
9. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.
Daluge SM; Purifoy DJ; Savina PM; St Clair MH; Parry NR; Dev IK; Novak P; Ayers KM; Reardon JE; Roberts GB
Antimicrob Agents Chemother; 1994 Jul; 38(7):1590-603. PubMed ID: 7526782
[TBL] [Abstract][Full Text] [Related]
10. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
11. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA
Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
Sluis-Cremer N; Arion D; Parniak MA
Cell Mol Life Sci; 2000 Sep; 57(10):1408-22. PubMed ID: 11078020
[TBL] [Abstract][Full Text] [Related]
13. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
[TBL] [Abstract][Full Text] [Related]
14. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
15. The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.
Boyer PL; Vu BC; Ambrose Z; Julias JG; Warnecke S; Liao C; Meier C; Marquez VE; Hughes SH
J Med Chem; 2009 Sep; 52(17):5356-64. PubMed ID: 19678643
[TBL] [Abstract][Full Text] [Related]
16. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Parikh UM; Bacheler L; Koontz D; Mellors JW
J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
[TBL] [Abstract][Full Text] [Related]
17. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
[TBL] [Abstract][Full Text] [Related]
18. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
Lennerstrand J; Chu CK; Schinazi RF
Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
20. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Tisdale M; Alnadaf T; Cousens D
Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
